EP Patent

EP1568769A1 — ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR

Assigned to Nonprofit Organization Translational Research Organization of Duchenne Muscular Dystrophy · Expires 2005-08-31 · 21y expired

What this patent protects

Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy compr…

USPTO Abstract

Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.

Drugs covered by this patent

Patent Metadata

Patent number
EP1568769A1
Jurisdiction
EP
Classification
—
Expires
2005-08-31
Drug substance claim
No
Drug product claim
No
Assignee
Nonprofit Organization Translational Research Organization of Duchenne Muscular Dystrophy
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.